Last reviewed · How we verify
NDV-3
At a glance
| Generic name | NDV-3 |
|---|---|
| Sponsor | NovaDigm Therapeutics, Inc. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Effect of Adjuvant & Route of Administration on Safety & Immunogenicity of NDV-3 Vaccine (PHASE1)
- Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis (PHASE1, PHASE2)
- Safety and Immunogenicity Study of a Recombinant Protein Vaccine (NDV-3) Against S.Aureus and Candida (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NDV-3 CI brief — competitive landscape report
- NDV-3 updates RSS · CI watch RSS
- NovaDigm Therapeutics, Inc. portfolio CI